Enter your email address below to sign up for our Email Alerts, featuring developments and analysis of the industry and related Equiscope information.


Under Rule 506(c), issuers may offer securities through means of general solicitation, provided that:

• all purchasers in the offering are accredited investors,

• the issuer takes reasonable steps to verify their accredited investor status, and

• certain other conditions in Regulation D are satisfied.

This Offering is limited to accredited investors only

An “accredited investor” is:

• a bank, insurance company, registered investment company, business development company, or small business investment company;

• an employee benefit plan (within the meaning of the Employee Retirement Income Security Act) if a bank, insurance company, or registered investment adviser makes the investment decisions, or if the plan has total assets in excess of $5 million;

• a tax exempt charitable organization, corporation or partnership with assets in excess of $5 million;

• a director, executive officer, or general partner of the company selling the securities;

• an enterprise in which all the equity owners are accredited investors;

• an individual with a net worth of at least $1 million, not including the value of his or her primary residence;

• an individual with income exceeding $200,000 in each of the two most recent calendar years or joint income with a spouse exceeding $300,000 for those years and a reasonable expectation of the same income level in the current year; or

• a trust with assets of at least $5 million, not formed only to acquire the securities offered, and whose purchases are directed by a person who meets the legal standard of having sufficient knowledge and experience in financial and business matters to be capable of evaluating the merits and risks of the prospective investment.

Electrotherapy uses electrical impulses to treat soft tissue injuries, neurological conditions and stimulate muscles to improve strength and sensation for a broad range of uses including pain management, cardiology, tissue repair, sports medicine and rehabilitation in humans as well as animals, in addition to esthetics / cosmetics.

Founded in 2012, Intelligent Bioenergetics (“Intelligent Bioenergetics”, the “Company”, “we” “our” or “us”) markets and sells electrotherapy devices manufactured by Biomedical Development Corp. to health and wellness professionals treating human and equine patients, and estheticians.

Since commencement of operations in July 2013, we have generated approximately $4.1 million in sales.
Our CEO and founder, John Thorp has clinically developed proven protocols over the past 30 years, based on more than 20,000 patients and 45,000 treatment hours with a 90% success rate in the reduction of chronic pain.

We believe bioenergetic technology has the potential to have a tremendous impact on healthcare by providing treatment designed for precise pain relief, neuromuscular rehabilitation and neurological therapies with science-based medicine that may outperform today’s current treatments for acute and chronic pain and disease. We intend to become the leading provider of bioenergetic technology worldwide.

Capital Raise: $2,700,000 | Price/Share: $0.50
Shares Offered: 5,400,000 | Structure: Series A Preferred Stock